The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

Aging and Cognitive FunctionsMultiple SclerosisDementia

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study

Lancet.

Chen H, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, Hystad P, Martin RV, Murray BJ, Jessiman B, Wilton AS, Kopp A, Burnett RT

doi: 10.1016/

Multiple Sclerosis

60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments

Front Neurol.

Kaufmann M, Puhan MA, Salmen A, Kamm CP, Manjaly ZM, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).

doi: 10.3389/fneur.2020.00156.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

Mult Scler.

Sotirchos ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, Glaister J, Filippatou A, Ogbuokiri E, Feldman S, Kwakyi O, Risher H, Crainiceanu C, Pham DL, Van Zijl PC, Mowry EM, Reich DS, Prince JL, Calabresi PA, Saidha S

doi: 10.1177/

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Transcriptome analysis of normal-appearing white matter reveals cortisol- and disease-associated gene expression profiles in multiple sclerosis

Acta Neuropathol Commun.

Melief J, Orre M, Bossers K, van Eden CG, Schuurman KG, Mason MRJ, Verhaagen J, Hamann J, Huitinga I

doi: 10.1186/s40478-019-0705-7.

COMMENTED

Multiple Sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Mult Scler J Exp Transl Clin.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR)

doi: 10.1177/2055217318814562.

Multiple Sclerosis

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study

Lancet Neurol.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA

doi: 10.1016/S1474-4422

Multiple Sclerosis

T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter

Sci Rep.

Kelemen P, Alaoui J, Sieron D, Chan A, Kamm CP, Heldner MR, Gralla J, Wiest R, Verma RK

doi: 10.1038/s41598-018-

Related content

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study

60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments

Vaccination Readiness in Multiple Sclerosis

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Transcriptome analysis of normal-appearing white matter reveals cortisol- and disease-associated gene expression profiles in multiple sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study

T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter